Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
trenzyme is a privately held German contract research organization focused on customized cell culture and recombinant protein production services for academic, biotechnology, and pharmaceutical customers. The company offers cell line development, including assay and production cell lines, GMP-compliant research cell banks, iPSC differentiation and characterization, immortalization, cell expansion, and recombinant protein expression and purification. Rather than advancing a proprietary therapeutic pipeline, trenzyme operates as a fee-for-service research partner supporting preclinical research, assay development, and biologics-related workflows. The company highlights ISO 9001:2015 quality management, modular project design, and support across mammalian, microbial, insect, and yeast-based protein expression approaches. Founded in 2000 and based in Konstanz, Germany, trenzyme appears to be an active private life sciences services company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on trenzyme.